The Centre for Clinical Genomics laboratory conducts clinical next-generation sequencing assays.
The mandate of the Centre for Clinical Genomics is to provide sustainable and scalable clinical diagnostic genomic testing for the population of BC. This testing requires high throughput sequencing capabilities and extensive bioinformatic expertise, which are made possible through partnerships with the BC Cancer Agency's Canada’s Michael Smith Genome Sciences Centre.
Assay test panels offered by the Centre for Clinical Genomics lab include:
- The Hereditary Cancer Program Panel: detects mutations in the 14 genes most commonly tested when screening for hereditary breast, ovarian, and colorectal cancer syndromes. This panel replaced BRCA1/2 testing in British Columbia in October 2014 and is available to patients across Canada.
Assay test panels undergoing clinical trials include:
- The Oncopanel: detects common somatic mutations in solid tumours.
- The Myeloid Panel: detects mutations in genes associated with myeloid malignancies including acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes.
The Centre for Clinical Genomics laboratory has been awarded accreditation by the College of American Pathologists (CAP).